{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:18:00Z","timestamp":1780319880680,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1124\/dmd.118.081570","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T19:16:17Z","timestamp":1531422977000},"page":"1453-1461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction"],"prefix":"10.1016","volume":"46","author":[{"given":"Jie","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.081570_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.phrs.2003.10.010","article-title":"Pharmacokinetic interactions between omeprazole\/pantoprazole and clarithromycin in health volunteers","volume":"49","author":"Calabresi","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.118.081570_bib2","first-page":"14","article-title":"Gender, but not CYP2C19 genotypes and CYP3A phenotypes, is a major determinant of ilaprazole pharmacokinetic","volume":"3","author":"Cao","year":"2015","journal-title":"Am J Life Sci"},{"key":"10.1124\/dmd.118.081570_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/aps.2012.64","article-title":"Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy","volume":"33","author":"Cao","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.118.081570_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0091270011408611","article-title":"Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole","volume":"52","author":"Cho","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081570_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425255.2013.813018","article-title":"The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment","volume":"9","author":"de Bortoli","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.118.081570_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":"Epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"54","author":"Dent","year":"2005","journal-title":"Gut"},{"key":"10.1124\/dmd.118.081570_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jps.21802","article-title":"Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates","volume":"99","author":"Fenneteau","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.081570_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11317220-000000000-00000","article-title":"A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling","volume":"48","author":"Hisaka","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.081570_bib9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2125.2007.03094.x","article-title":"Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians","volume":"65","author":"Hunfeld","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081570_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP44297","article-title":"Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem","volume":"44","author":"Klotz","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081570_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","article-title":"CYP2C19 polymorphism and proton pump inhibitors","volume":"95","author":"Klotz","year":"2004","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.118.081570_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cca.2008.02.003","article-title":"CYP3A5 CYP2C19 genotypes","volume":"391","author":"Li","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1124\/dmd.118.081570_bib13","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/ajg.2010.324","article-title":"Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China","volume":"105","author":"Li","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.118.081570_bib14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4155\/bio.13.103","article-title":"Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS","volume":"5","author":"Ma","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1124\/dmd.118.081570_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkf172","article-title":"Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration","volume":"50","author":"Mainz","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.118.081570_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02976545","article-title":"Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC\/ESI mass spectrometry","volume":"22","author":"Myung","year":"1999","journal-title":"Arch Pharm Res"},{"key":"10.1124\/dmd.118.081570_bib17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2147\/DDDT.S131797","article-title":"Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer","volume":"11","author":"Park","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/dmd.118.081570_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1067\/mcp.2000.109155","article-title":"A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease","volume":"68","author":"Periclou","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081570_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00228-005-0063-1","article-title":"Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype","volume":"62","author":"Qiao","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081570_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12272-001-1171-z","article-title":"In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients","volume":"31","author":"Ren","year":"2008","journal-title":"Arch Pharm Res"},{"key":"10.1124\/dmd.118.081570_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jms.1311","article-title":"An integrated method for metabolite detection and identification using a linear ion trap\/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection","volume":"43","author":"Ruan","year":"2008","journal-title":"J Mass Spectrom"},{"key":"10.1124\/dmd.118.081570_bib22","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/14656566.2016.1232389","article-title":"Ilaprazole for the treatment of gastro-esophageal reflux","volume":"17","author":"Savarino","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/dmd.118.081570_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/00498254.2011.622416","article-title":"Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5","volume":"42","author":"Seo","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.081570_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.5414\/CPP44557","article-title":"Mass balance study of [14C] rabeprazole following oral administration in healthy subjects","volume":"44","author":"Setoyama","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081570_bib25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00228-006-0152-9","article-title":"Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes","volume":"62","author":"Shimizu","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081570_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/apt.12860","article-title":"The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study","volume":"40","author":"Shin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.118.081570_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mcp.2002.125559","article-title":"Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6\u03b2-hydroxycortisol","volume":"72","author":"Ushiama","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081570_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3109\/00498254.2016.1156185","article-title":"Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.081570_bib29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/13696998.2016.1194277","article-title":"Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China","volume":"19","author":"Xuan","year":"2016","journal-title":"J Med Econ"},{"key":"10.1124\/dmd.118.081570_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40261-016-0446-3","article-title":"A randomized, double-blind, active-controlled, multi-center study of ilaprazole in the treatment of reflux esophagitis","volume":"36","author":"Xue","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1124\/dmd.118.081570_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0009-9236(95)90192-2","article-title":"Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4\u2032-hydroxylation status","volume":"58","author":"Yasuda","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081570_bib32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/bmc.1416","article-title":"Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS\/MS and HPLC-NMR experiments","volume":"24","author":"Zhou","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.118.081570_bib33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/aps.2009.120","article-title":"An improved LC-MS\/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study","volume":"30","author":"Zhou","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.118.081570_bib34","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1124\/dmd.106.009241","article-title":"Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography\/high resolution mass spectrometry data","volume":"34","author":"Zhu","year":"2006","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562405582X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562405582X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.081570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:36:54Z","timestamp":1739903814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562405582X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S009095562405582X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.081570","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.081570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}